CLAIMS

1. Use of a compound of the general formula (I)



(I)

wherein

$V^1$, $V^2$, $V^3$, and $V^4$ independently are selected from a carbon atom, a non-quaternary nitrogen atom, an oxygen atom, and a sulfur atom, and where $V^4$ further may be selected from a bond, so that $-V^1-V^2-V^3-V^4-$ together with the atoms to which $V^1$ and $V^4$ are attached form an aromatic or heteroaromatic ring;

$R^1$, $R^2$, $R^3$, and $R^4$, when attached to a carbon atom, independently are selected from hydrogen, optionally substituted $C_{1-6}$-alkyl, optionally substituted $C_{2-6}$-alkenyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{2-6}$-alkenyloxy, carboxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyloxy, formyl, amino, mono- and di($C_{1-6}$-alkyl)amino, carbamoyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, cyano, carbamido, mono- and di($C_{1-6}$-alkyl)aminocarbonylamino, $C_{1-6}$-alkanoyloxy, $C_{1-6}$-alkylsulphonyl, $C_{1-6}$-alkylsulphinyl, aminosulfonyl, mono- and di($C_{1-6}$-alkyl)aminosulfonyl, nitro, optionally substituted $C_{1-6}$-alkylthio, aryl, aryloxy, arylcarbonyl, arylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylcarbonyl, heteroaryl, heteroaryloxy, heteroarylamino, heteroarylcarbonyl, and halogen, where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

$R^1$, $R^2$, $R^3$, and $R^4$, when attached to a nitrogen atom, independently are selected from hydrogen, optionally substituted $C_{1-6}$-alkyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, formyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, amino, $C_{1-6}$-alkylcarbonylamino, mono- and di($C_{1-6}$-alkyl)amino, $C_{1-6}$-alkylsulphonyl, $C_{1-6}$-alkylsulphinyl, aryl, aryloxy, arylcarbonyl, arylamino,

heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, heterocyclylamino, heteroaryl, heteroaryloxy, heteroarylcarbonyl, and heteroarylamino; where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

or $R^1$ and $R^2$ together with the carbon atoms to which they are attached form a ring, e.g. an aromatic ring, a carbocyclic ring, a heterocyclic ring or a heteroaromatic ring, in particular an aromatic ring, a heterocyclic ring or a heteroaromatic ring;

$X^1$ and $X^2$ are independently selected from halogen, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{1-6}$-alkylcarbonyloxy, amino, mono- and di($C_{1-6}$-alkyl)amino, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, mono- and di($C_{1-6}$-alkyl)amino-carbonylamino, $C_{1-6}$-alkanoyloxy, mercapto, optionally substituted $C_{1-6}$-alkylthio, $C_{1-6}$-alkylsulfonyl, mono- and di($C_{1-6}$-alkyl)aminosulfonyl, aryloxy, arylamino, heterocyclyloxy, heterocyclylamino, heteroaryloxy and heteroarylamino, where any $C_{1-6}$-alkyl as an amino or sulphur substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

$>Y(=Q)_n$ is selected from >C=O, >C=S, >S=O and $>S(=O)_2$; and

$R^N$ is selected from the group consisting of hydrogen, optionally substituted $C_{1-6}$-alkyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, formyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, amino, $C_{1-6}$-alkylcarbonylamino, mono- and di($C_{1-6}$-alkyl)amino, $C_{1-6}$-alkylsulphonyl, and $C_{1-6}$-alkylsulphinyl; where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s); and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

2. The use according to claim 1, wherein $R^1$, $R^2$, $R^3$ and $R^4$ are not all hydrogen.

3. The use according to any one of the preceding claims, wherein the ring is selected from a benzene ring and a pyridine ring where the nitrogen atom represents $V^3$.

4. The use according to any one of the preceding claims, wherein $R^1$ is selected from hydrogen, halogen, $C_{1-6}$-alkyl, trifluoromethyl and $C_{1-6}$-alkoxy, when $V^1$ is a carbon atom.

5. The use according to any one of the preceding claims, wherein $R^2$ is selected from hydrogen, halogen, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl, when $V^2$ is a carbon atom.

6. The use according to any one of the preceding claims, wherein $R^3$ is selected from hydrogen, optionally substituted $C_{1-6}$-alkoxy, halogen, cyano, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, and mono- and di($C_{1-6}$-alkyl)aminosulfonyl, when $V^3$ is a carbon atom.

7. The use according to any one of the preceding claims, wherein $R^4$ is hydrogen, when $V^4$ is a carbon atom.

8. The use according to any one of the preceding claims, wherein $X^1$ and $X^2$ independently are selected from hydroxy, OAc, $NH_2$, $NMe_2$, NHAc, $NHSO_2Me$ and $NHCONMe_2$.

9. The use according to any one of the preceding claims, wherein $X^1$ and $X^2$ are the same.

10. The use according to any one of the preceding claims, wherein Y is a carbon atom and Q is an oxygen atom, i.e. $>Y(=Q)_n$ is >C=O, and $R^N$ is selected from hydrogen, $C_{1-6}$-alkyl, amino, and $C_{1-6}$-alkylcarbonylamino.

11. The use according to any one of the preceding claims, wherein $V^1$, $V^2$, $V^3$, $V^4$ all are a carbon atom, $>Y(=Q)_n$ is >C=O, and $R^N$ is hydrogen.

12. The use according to any one of the preceding claims, wherein $R^4$ is hydrogen.

13. The use according to claim 12, wherein $R^3$ and $R^4$ both are hydrogen.

14. The use according to any one of the claims 11-13, wherein $R^1$ is $C_{1-4}$-alkyl and $R^2$ is halogen.

15. The use according to any one of the claims 11-13, wherein $R^1$ and $R^2$ together with the carbon atoms to which they are attached form an aromatic ring or a carbocyclic ring.

16. The use according to any one of the claims 11-15, wherein each of $X^1$ and $X^2$ independently are selected from halogen, hydroxy, $C_{1-4}$-alkoxy, amino, and dimethylamino.

17. The use according to claim 12, wherein $R^1$, $R^2$ and $R^4$ all are hydrogen.

18. The use according to any one of the claims 11 and 17, wherein $R^3$ is selected from hydrogen, halogen, nitro, $C_{1-4}$-alkyl, $C_{1-4}$-alkoxy, trifluoromethoxy, amino, carboxy, and dimethylaminocarbonyl.

19. The use according to any one of the claims 17-18, wherein each of $X^1$ and $X^2$ independently are selected from halogen, hydroxy, $C_{1-4}$-alkoxy, amino, and dimethylamino.

20. The use according to claim 12, wherein $R^2$, $R^3$ and $R^4$ all are hydrogen.

21. The use according to any one of the claims 11 and 20, wherein $R^1$ is selected from fluoro, chloro, bromo, $C_{1-4}$-alkyl, trifluoromethyl, $C_{1-4}$-alkoxy, and dimethylaminocarbonyl.

22. The use according to any one of the claims 20-21, wherein each of $X^1$ and $X^2$ independently are selected from halogen, hydroxy, $C_{1-4}$-alkoxy, amino, and dimethylamino.

23. The use according to any one of the claims 11 and 12, wherein $R^1$ is selected from halogen, $C_{1-4}$-alkyl, trifluoromethyl, $C_{1-4}$-alkoxy, and dimethylaminocarbonyl, $R^2$ is selected from hydrogen and halogen, and $R^3$ is selected from hydrogen, halogen, $C_{1-4}$-alkyl, and amino; where $R^2$ and $R^3$ are not both hydrogen.

24. Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIa)




(IIa)

wherein

$R^1$ is selected from hydrogen, halogen, $C_{1-6}$-alkyl, trifluoromethyl and $C_{1-6}$-alkoxy;

$R^2$ is selected from hydrogen, halogen, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl;

$R^3$ is selected from hydrogen, optionally substituted $C_{1-6}$-alkoxy, halogen, cyano, and optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, and mono- and di($C_{1-6}$-alkyl)aminosulfonyl;

Z is CH or N; and

$X^1$ and $X^2$ are independently selected from halogen, $OR^6$, $OCOR^5$, $N(R^6)_2$, $NHCOR^5$, $NHSO_2R^5$, and $NHCON(R^6)_2$, wherein $R^5$ is selected from $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each $R^6$ independently is selected from hydrogen, $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl; and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

25. Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIb)



(IIb)

wherein

$R^1$, $R^2$, and $R^3$, when attached to a carbon atom, independently are selected from hydrogen, optionally substituted $C_{1-6}$-alkyl, optionally substituted $C_{2-6}$-alkenyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{2-6}$-alkenyloxy, carboxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyloxy, formyl, amino, mono- and di($C_{1-6}$-alkyl)amino, carbamoyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, cyano, carbamido, mono- and di($C_{1-6}$-alkyl)aminocarbonylamino, $C_{1-6}$-alkanoyloxy, $C_{1-6}$-alkylsulphonyl, $C_{1-6}$-alkylsulphinyl, aminosulfonyl, mono- and di($C_{1-6}$-alkyl)aminosulfonyl,

nitro, optionally substituted $C_{1-6}$-alkylthio, and halogen, where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s); and

$R^1$, $R^2$, and $R^3$, when attached to a nitrogen atom, independently are selected from hydrogen, optionally substituted $C_{1-6}$-alkyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, formyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, amino, $C_{1-6}$-alkylcarbonylamino, mono- and di($C_{1-6}$-alkyl)amino, $C_{1-6}$-alkylsulphonyl, and $C_{1-6}$-alkylsulphinyl; where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

or wherein $R^1$ and $R^2$ together with the carbon and/or nitrogen atoms to which they are attached form a heterocyclic ring, a heteroaromatic ring, an aromatic ring or a carbocyclic ring;

Z is CH or N; and

$X^1$ and $X^2$ are independently selected from halogen, $OR^6$, $OCOR^5$, $N(R^6)_2$, $NHCOR^5$, $NHSO_2R^5$, and $NHCON(R^6)_2$, wherein $R^5$ is selected from $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each $R^6$ independently is selected from hydrogen, $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl; and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

26. Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIc)



(IIc)

wherein

$R^1$ is selected from hydrogen, halogen, $C_{1-6}$-alkyl, trifluoromethyl and $C_{1-6}$-alkoxy;

$R^2$ is selected from hydrogen, halogen, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl;

$R^3$ is selected from hydrogen, optionally substituted $C_{1-6}$-alkoxy, halogen, cyano, and optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, and mono- and di($C_{1-6}$-alkyl)aminosulfonyl;

Z is CH or N; and

one of $X^1$ and $X^2$ is selected from halogen, $OR^6$, $OCOR^5$, $N(R^6)_2$, $NHCOR^5$, $NHSO_2R^5$, and $NHCON(R^6)_2$, wherein $R^5$ is selected from $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each $R^6$ independently is selected from hydrogen, $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl; and the other of $X^1$ and $X^2$ is selected from optionally substituted $C_{1-6}$-alkyl, optionally substituted $C_{2-6}$-alkenyl, carboxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, formyl, carbamoyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, cyano, aryl, arylcarbonyl, heterocyclyl, heterocyclylcarbonyl, heteroaryl, heteroarylcarbonyl, where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted; and

pharmaceutically acceptable salts and prodrugs thereof (as defined further above);

for the preparation of a medicament for the treatment of cancer in a mammal.

27. Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IId)



(IId)

wherein

$R^1$, $R^2$, and $R^3$, when attached to a carbon atom, independently are selected from hydrogen, optionally substituted $C_{1-6}$-alkyl, optionally substituted $C_{2-6}$-alkenyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{2-6}$-alkenyloxy, carboxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyloxy, formyl, amino, mono- and di($C_{1-6}$-alkyl)amino, carbamoyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylsulphonylamino, cyano, carbamido, mono- and di($C_{1-6}$-alkyl)aminocarbonylamino, $C_{1-6}$-alkanoyloxy, $C_{1-6}$-alkylsulphonyl, $C_{1-6}$-alkylsulphinyl, aminosulfonyl, mono- and di($C_{1-6}$-alkyl)aminosulfonyl, nitro, optionally substituted $C_{1-6}$-alkylthio, and halogen, where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s); and

$R^1$, $R^2$, and $R^3$, when attached to a nitrogen atom, independently are selected from hydrogen, optionally substituted $C_{1-6}$-alkyl, hydroxy, optionally substituted $C_{1-6}$-alkoxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, formyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, amino, $C_{1-6}$-alkylcarbonylamino, mono- and di($C_{1-6}$-alkyl)amino, $C_{1-6}$-alkylsulphonyl, and $C_{1-6}$-alkylsulphinyl; where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

or wherein $R^1$ and $R^2$ together with the carbon and/or nitrogen atoms to which they are attached form a heterocyclic ring, a heteroaromatic ring, an aromatic ring or a carbocyclic ring;

Z is CH or N; and

one of $X^1$ and $X^2$ is selected from halogen, $OR^6$, $OCOR^5$, $N(R^6)_2$, $NHCOR^5$, $NHSO_2R^5$, and $NHCON(R^6)_2$, wherein $R^5$ is selected from $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each $R^6$ independently is selected from hydrogen, $C_{1-6}$-alkyl, optionally substituted aryl and optionally substituted heteroaryl; and the other of $X^1$ and $X^2$ is selected from optionally substituted $C_{1-6}$-alkyl, optionally substituted $C_{2-6}$-alkenyl, carboxy, optionally substituted $C_{1-6}$-alkoxycarbonyl, optionally substituted $C_{1-6}$-alkylcarbonyl, formyl, carbamoyl, mono- and di($C_{1-6}$-alkyl)aminocarbonyl, cyano, aryl, arylcarbonyl, heterocyclyl, heterocyclylcarbonyl, heteroaryl, heteroarylcarbonyl, where any $C_{1-6}$-alkyl as an amino substituent is optionally substituted with hydroxy, $C_{1-6}$-alkoxy, amino, mono- and di($C_{1-6}$-alkyl)amino, carboxy, $C_{1-6}$-alkylcarbonylamino, $C_{1-6}$-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted; and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

28. The use according to any one of the preceding claims, wherein the compound is selected from Items 1 to 225 listed herein.

29. The use according to any one of the preceding claims, wherein the medicament further comprises one or more other chemotherapeutic agents.

30. A compound as defined in any one of the claims 1-28 for use as a medicament, with the proviso that the compound is not one selected from 3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one and acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

31. A compound of the general formula (I)



(I)

as defined in any one of the claims 1-23, with the proviso that the compound is not one selected from

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,
3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;
3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one ;
3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;
5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;
5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;
3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;
3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;
6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;
acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and
acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

32. A 3,3-Diphenyl-1,3-dihydro-indol-2-one type compound of the formula (II)



(II)

as defined in any one of the claims 24-28, with the proviso that the compound is not one selected from:

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,
3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;
3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one ;
3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;
5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;
5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;
3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;
3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;
6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;
acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and
acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

33. A pharmaceutical composition comprising a compound as defined in any one of the claims 1-28 and a pharmaceutically acceptable carrier.